{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:12:57Z","timestamp":1787026377643,"version":"build-2736575974"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T00:00:00Z","timestamp":1560902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008994","name":"Universidade de Bras\u00edlia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008994","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"DOI":"10.3389\/fendo.2019.00364","type":"journal-article","created":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T00:14:23Z","timestamp":1560903263000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Transient Elastography and Controlled Attenuation Parameter (CAP) in the Assessment of Liver Steatosis in Severe Adult Growth Hormone Deficiency"],"prefix":"10.3389","volume":"10","author":[{"given":"Adriana Claudia Lopes","family":"Carvalho-Furtado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela Mariano","family":"Carvalho-Louro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neysa Aparecida Tinoco","family":"Regattieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo Palmeira","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luiza Ricardo Nogueira","family":"Montenegro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 Metzker","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patr\u00edcia Souza","family":"Pirangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana Ansaneli","family":"Naves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,6,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1159\/000182734","article-title":"Discontinuation of growth hormone therapy in growth-hormone-deficient patients: assessment of body fat mass using bioelectrical impedance","volume":"39","author":"Colle","year":"1993","journal-title":"Horm Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/j.1365-2265.1995.tb01860.x","article-title":"Abnormal body composition and reduced bone mass in growth hormone deficient hypopituitary adults","volume":"42","author":"Beshyah","year":"1995","journal-title":"Clin Endocrinol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1210\/jc.82.3.727","article-title":"Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure","volume":"82","author":"Johannsson","year":"1997","journal-title":"J Clin Endocrinol Metab."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/S0140-6736(05)66378-7","article-title":"The metabolic syndrome","volume":"365","author":"Eckel","year":"2005","journal-title":"Lancet."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism."},{"key":"B6","volume-title":"Fatty Liver Disease: NASH and Related Disorders.","author":"Farrell","year":"2005"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1053\/j.gastro.2012.04.001","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology","volume":"142","author":"Chalasani","year":"2012","journal-title":"Gastroenterology."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.cgh.2012.10.001","article-title":"Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review","volume":"10","author":"White","year":"2012","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/j.1467-789X.2009.00594.x","article-title":"Non-alcoholic fatty liver disease is associated with cardiovascular disease risk markers","volume":"10","author":"Edens","year":"2009","journal-title":"Obes Rev."},{"key":"B10","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1136\/gut.52.6.914","article-title":"Non-alcoholic steatohepatitis and hepatic steatosis in patients with adult onset growth hormone deficiency","volume":"52","author":"Ichikawa","year":"2003","journal-title":"Gut."},{"key":"B11","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/nrgastro.2016.3","article-title":"Management of NAFLD: a stage-based approach","volume":"13","author":"Rinella","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","article-title":"Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis","volume":"66","author":"Karlas","year":"2017","journal-title":"J Hepatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/nrgastro.2013.175","article-title":"Noninvasive evaluation of NAFLD","volume":"10","author":"Castera","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1148\/radiol.2018170601","article-title":"Quantitative elastography methods in liver disease: current evidence and future directions","volume":"286","author":"Kennedy","year":"2018","journal-title":"Radiology."},{"key":"B15","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/j.1478-3231.2012.02820.x","article-title":"Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography","volume":"32","author":"de Ledinghen","year":"2012","journal-title":"Liver Int."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.ultrasmedbio.2010.07.005","article-title":"Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes","volume":"36","author":"Sasso","year":"2010","journal-title":"Ultrasound Med Biol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1038\/ajg.2017.389","article-title":"Prognostic value of controlled attenuation parameter by transient elastography","volume":"112","author":"Liu","year":"2017","journal-title":"Am J Gastroenterol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/nrgastro.2018.10","article-title":"Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD","volume":"15","author":"Tapper","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B19","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.aohep.2018.09.003","article-title":"Transient hepatic elastography has the best performance to evaluate liver fibrosis in non-alcoholic fatty liver disease (NAFLD)","volume":"18","author":"Tovo","year":"2019","journal-title":"Ann Hepatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1385\/JCD:6:2:75","article-title":"Clinical applications of body composition measurements using DXA","volume":"6","author":"Albanese","year":"2003","journal-title":"J Clin Densitom."},{"key":"B21","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1159\/000453364","article-title":"Diagnostic accuracy of controlled attenuation parameter for detecting hepatic steatosis in patients with chronic liver disease","volume":"24","author":"Andrade","year":"2017","journal-title":"GE Port J Gastroenterol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jhep.2015.02.045","article-title":"Hepatic steatosis and cardiovascular disease outcomes: an analysis of the Framingham Heart Study","volume":"63","author":"Mellinger","year":"2015","journal-title":"J Hepatol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"11053","DOI":"10.3748\/wjg.v21.i39.11053","article-title":"Endocrine causes of nonalcoholic fatty liver disease","volume":"21","author":"Marino","year":"2015","journal-title":"World J Gastroenterol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2174\/1570161114666161007164510","article-title":"Link between metabolic syndrome and insulin resistance","volume":"15","author":"Gluvic","year":"2017","journal-title":"Curr Vasc Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1210\/er.16.1.63","article-title":"Clinical aspects of growth hormone deficiency in adults","volume":"16","author":"de Boer","year":"1995","journal-title":"Endocr Rev."},{"key":"B26","doi-asserted-by":"crossref","DOI":"10.1007\/s40519-019-00640-9","article-title":"Eating behavior and metabolic syndrome over time","volume-title":"Eat Weight Disord.","author":"Song","year":"2019"},{"key":"B27","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2174\/1872208311666170227112013","article-title":"The metabolic syndrome and the relevance of nutrients for its onset","volume":"11","author":"Schnack","year":"2017","journal-title":"Recent Pat Biotechnol."},{"key":"B28","doi-asserted-by":"crossref","DOI":"10.1055\/a-0767-6361","article-title":"Development of the metabolic syndrome: study design and baseline data of the lufthansa prevention study (LUPS), a prospective observational cohort survey","volume-title":"Exp Clin Endocrinol Diabetes.","author":"Muller-Wieland","year":"2018"},{"key":"B29","doi-asserted-by":"publisher","first-page":"947","DOI":"10.2337\/diabetes.45.7.947","article-title":"Insulin action and age","volume":"45","author":"Ferrannini","year":"1996","journal-title":"Diabetes."},{"key":"B30","doi-asserted-by":"publisher","first-page":"B225","DOI":"10.1093\/gerona\/57.6.B225","article-title":"Aging is associated with resistance to effects of leptin on fat distribution and insulin action","volume":"57","author":"Ma","year":"2002","journal-title":"J Gerontol A Biol Sci Med Sci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.arr.2009.06.001","article-title":"Age-related changes in total and regional fat distribution","volume":"8","author":"Kuk","year":"2009","journal-title":"Ageing Res Rev."},{"key":"B32","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1210\/jc.2009-1326","article-title":"Prevalence of metabolic syndrome in adult hypopituitary growth hormone (GH)-deficient patients before and after GH replacement","volume":"95","author":"Attanasio","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"key":"B33","first-page":"S33","article-title":"The value of IGF1 estimation in adults with GH deficiency","volume-title":"Eur J Endocrinol.","author":"Mukherjee","year":"2009"},{"key":"B34","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1210\/jc.82.1.82","article-title":"Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment","volume":"82","author":"Attanasio","year":"1997","journal-title":"J Clin Endocrinol Metab."},{"key":"B35","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1046\/j.1365-2265.2003.01884.x","article-title":"Determinants of IGF-I status in a large cohort of growth hormone-deficient (GHD) subjects: the role of timing of onset of GHD","volume":"59","author":"Lissett","year":"2003","journal-title":"Clin Endocrinol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/jgh.12437","article-title":"Relationship between serum circulating insulin-like growth factor-1 and liver fat in the United States","volume":"29","author":"Runchey","year":"2014","journal-title":"J Gastroenterol Hepatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/cen.13042","article-title":"Liver fat in adults with GH deficiency: comparison to matched controls and the effect of GH replacement","volume":"85","author":"Meienberg","year":"2016","journal-title":"Clin Endocrinol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology."},{"key":"B39","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jhep.2015.04.006","volume":"63","year":"2015","journal-title":"J Hepatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1210\/er.2008-0009","article-title":"Causes and metabolic consequences of Fatty liver","volume":"29","author":"Stefan","year":"2008","journal-title":"Endocr Rev."},{"key":"B41","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1007\/s12072-018-9893-7","article-title":"Metabolic effects of reduced growth hormone action in fatty liver disease","volume":"12","author":"Rufinatscha","year":"2018","journal-title":"Hepatol Int."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.3390\/ijms18071447","article-title":"The role of growth hormone and insulin-like growth factor-I in the liver","volume":"42","author":"Takahashi","year":"2017","journal-title":"Int J Mol Sci."},{"key":"B43","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1210\/jc.2012-2006","article-title":"Discontinuing long-term GH replacement therapy\u2013a randomized, placebo-controlled crossover trial in adult GH deficiency","volume":"97","author":"Filipsson Nystrom","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"key":"B44","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1210\/jc.2012-2940","article-title":"Metabolic profile in growth hormone-deficient (GHD) adults after long-term recombinant human growth hormone (rhGH) therapy","volume":"98","author":"Claessen","year":"2013","journal-title":"J Clin Endocrinol Metab."}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2019.00364\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,22]],"date-time":"2019-09-22T21:43:50Z","timestamp":1569188630000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2019.00364\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,19]]},"references-count":44,"alternative-id":["10.3389\/fendo.2019.00364"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2019.00364","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,19]]},"article-number":"364"}}